Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Kalender
| 2021-10-21 | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | Kvartalsrapport 2021-Q2 |
| 2021-05-14 | Ordinarie utdelning HNSA 0.00 SEK |
| 2021-05-12 | Årsstämma 2021 |
| 2021-04-22 | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | Bokslutskommuniké 2020 |
| 2020-10-22 | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | Kvartalsrapport 2020-Q2 |
| 2020-06-24 | Ordinarie utdelning HNSA 0.00 SEK |
| 2020-06-23 | Årsstämma 2020 |
| 2020-04-28 | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | Bokslutskommuniké 2019 |
| 2019-10-31 | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | Ordinarie utdelning HNSA 0.00 SEK |
| 2019-05-22 | Årsstämma 2019 |
| 2019-04-29 | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | Bokslutskommuniké 2018 |
| 2018-11-01 | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | Kvartalsrapport 2018-Q2 |
| 2018-05-30 | Ordinarie utdelning HNSA 0.00 SEK |
| 2018-05-29 | Årsstämma 2018 |
| 2018-04-25 | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | Bokslutskommuniké 2017 |
| 2017-12-22 | Extra Bolagsstämma 2017 |
| 2017-11-14 | Kvartalsrapport 2017-Q3 |
| 2017-07-20 | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | Ordinarie utdelning HNSA 0.00 SEK |
| 2017-05-23 | Årsstämma 2017 |
| 2017-04-26 | Kvartalsrapport 2017-Q1 |
| 2017-02-15 | Bokslutskommuniké 2016 |
| 2016-11-21 | Extra Bolagsstämma 2016 |
| 2016-11-09 | Kvartalsrapport 2016-Q3 |
| 2016-07-21 | Kvartalsrapport 2016-Q2 |
| 2016-05-11 | Årsstämma 2016 |
| 2016-04-28 | Ordinarie utdelning HNSA 0.00 SEK |
| 2016-04-27 | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | Bokslutskommuniké 2015 |
| 2015-10-28 | Kvartalsrapport 2015-Q3 |
| 2015-08-25 | Kvartalsrapport 2015-Q2 |
| 2015-04-17 | Ordinarie utdelning HNSA 0.00 SEK |
| 2015-04-16 | Årsstämma 2015 |
| 2015-04-16 | Kvartalsrapport 2015-Q1 |
| 2015-02-05 | Bokslutskommuniké 2014 |
| 2014-07-25 | Kvartalsrapport 2014-Q2 |
| 2014-06-04 | Ordinarie utdelning HNSA 0.00 SEK |
| 2014-06-03 | Årsstämma 2014 |
| 2014-03-05 | Extra Bolagsstämma 2014 |
| 2014-02-05 | Bokslutskommuniké 2013 |
| 2013-07-25 | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | Ordinarie utdelning HNSA 0.00 SEK |
| 2013-05-06 | Årsstämma 2013 |
| 2013-02-07 | Bokslutskommuniké 2012 |
| 2012-09-28 | Kapitalmarknadsdag 2012 |
| 2012-07-26 | Kvartalsrapport 2012-Q2 |
| 2012-05-14 | Årsstämma 2012 |
| 2012-02-09 | Bokslutskommuniké 2011 |
| 2012-01-09 | Extra Bolagsstämma 2011 |
| 2011-07-28 | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | Årsstämma 2011 |
| 2011-05-06 | Ordinarie utdelning HNSA 0.00 SEK |
| 2010-04-30 | Ordinarie utdelning HNSA 0.00 SEK |
| 2010-02-10 | Bokslutskommuniké 2009 |
| 2009-07-30 | Kvartalsrapport 2009-Q1 |
| 2009-05-12 | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | Ordinarie utdelning HNSA 0.00 SEK |
| 2009-04-29 | Årsstämma 1 |
Lund November 2, 2020. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 23, 2020 and has the following composition:
- Natalie Berner representing Redmile Group
- Thomas Olausson
- Jannis Kitsakis representing AP4
- Ulf Wiinberg, Chairman of the Board
The Chairman of the Board shall also summon the first meeting of the Nomination Committee.
The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.
The proposals of the Nomination Committee will be presented in the notice of the Annual General Meeting 2021 and will be published on Hansa Biopharma's website.
Shareholders wishing to submit comments or proposals to the Nomination Committee may do so via e-mail to ir@hansabiopharma.comor by letter to Hansa Biopharma, Nomination Committee, Box 785, 220 07 Lund, Sweden.
This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail:
Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: